Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide

Cancer

Volumn 83, Issue 4, 1998, Pages 739-747

  Hinkle, George H ^a   Burgers, John K ^b   Neal, Charles E ^c   Texter, John H ^d   Kahn, Daniel ^e   Williams, Richard D ^e   Maguire, Robert ^f   Rogers, Barbara ^f   Olsen, John O ^a   Badalament, Robert A ^g  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b Riverside Hospital   (United States)

^c MEMORIAL MEDICAL CENTER   (United States)

^d SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f Cytogen Corporation   (United States)

^g Rochester Urology PC   (United States)

Author keywords

Antibody imaging; Detection; Prostate carcinoma; Radioimmunoscintigraphy

Indexed keywords

CAPROMAB PENDETIDE IN 111; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER SCREENING; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; IMMUNOSCINTIGRAPHY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOCONJUGATES; INDIUM RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIOIMMUNODETECTION; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 15644381758     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980815)83:4<739::AID-CNCR16>3.0.CO;2-T     Document Type: Article

References (25)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. Ca Cancer J Clin 1997;47:5-27.
2. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-4.
3. Saitoh H, Yoshida K-I, Uchijima Y, Kobayashi N, Suwata J, Kamata S. Two different lymph node metastatic patterns of a prostate cancer. Cancer 1990;65:1843-6.
4. Hricak H, Dooms GC, Jeffrey RB, et al. Prostatic carcinoma: staging by clinical assessment, CT and MR imaging. Radiology 1987;162:331-6.
5. Doerr RJ, Abdel-Nabi H, Krag D, Mitchell E. Radiolabeled antibody imaging in the management of colorectal cancer: results of a multicenter clinical study. Ann Surg 1991;214: 118-24.
6. Babaian RJ, Lamki LM. Radioimmunoscintigraphy of prostate cancer. Semin Nucl Med 1989;19:309-21.
7. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7:927-36.
8. Lopes AD, Davis WL, Rosenstraus MJ. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from anti-prostate monoclonal antibody 7E11-C5.3. Cancer Res 1990;50:6423-9.
9. 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate 1991;18: 229-41.
10. Catalona WJ, Stein AJ. Staging errors in clinically localized prostatic cancer. J Urol 1982;127:452-6.
11. Carter HB, Hamper UM, Sheth S, Sanders RC, Epstein JI, Walsh PC. Evaluation of transrectal ultrasound in the early detection of prostate cancer. J Urol 1989;142:1008-10.
12. McSherry SA, Levy F, Schiebler ML, Keefe B, Dent GA, Mohler JL. Preoperative prediction of pathological tumor volume and stage in clinically localized prostate cancer. J Urol 1991;146:85-9.
13. Heiken JP, Forman HP, Brown JJ. Neoplasms of the bladder, prostate and testis. Radiol Clin North Am 1994;32:81-98.
14. Spencer JA, Golding SJ. Patterns of lymphatic metastases at recurrence of prostate cancer: CT findings. Clin Radiol 1994; 49:404-7.
15. Goldenberg DM, DeLand FH, Bennett SJ, Primus FJ, Nelson MO, Flanigan RC, et al. Radioimmunodetection of prostate cancer. In vivo use of radioactive antibodies against prostatic acid phosphatase for diagnostic and detection of prostatic cancer by nuclear imaging. JAMA 1983;250:630-5.
16. Dillman RO, Beauregard J, Ryan KP, Hagan PL, Clutter M, Amox D, et al. Radioimmunodetection of cancer with the use of indium-111-labeled monoclonal antibodies. NCI Monogr 1987;3:33-6.
17. Rosenstraus MJ, Davis WJ, Lopes AD, D'Aleo C, Gilman S. In vitro and in vivo reactivity of anti-prostate monoclonal antibody immunoconjugate 7E11-C5.3-GYK-DTPA. Antibody Immunoconjugates Radiopharm 1990;3:54.
18. Abdel-Nabi H, Wright GL, Gulfo JV, Petrylak DP, Neal CE, Texter JE, et al. Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Semin Urol 1992;X(1):45-54.
19. Neal CE, Baker MR, Texter JH. Prostate imaging with antibodies. Appl Radiol 1992;21:39-46.
20. Maguire RT, Pascucci VL, Maroli AN, Gulfo JV. Immunoscintigraphy in patients with colorectal, ovarian and prostate cancer. Cancer 1993;72:3453-62.
21. Kahn D, Williams RD, Seldin DW, Libertino JA, Hirschhorn M, Dreicer R, et al. Radioimmunoscintigraphy with indium-111 labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 1994;152:1490-5.
22. Babaian RJ, Sayer J, PodoloffDA, Steelhammer LC, Bhadkamkar VA, Gulfo JV. Radioimmunoscintigraphy of pelvic lymph nodes with indium-111 labeled monoclonal antibody CYT-356. J Urol 1994;152:1952-5.
23. Burgers JK, Hinkle GH, Haseman MK. Monoclonal antibody imaging of recurrent and metastatic prostate cancer. Semin Urol 1995;XIII:103-12.
24. Sodee DB, Conant R, Chalfant M, Miron S, Klein E, Bahnson R, et al. Preliminary imaging results using In-111 labeled CYT-356 (ProstaScint™) in the detection of recurrent prostate cancer. Clin Nucl Med 1996;21:759-67.
25. Kahn D, Williams RD, Haseman MK, Reed NL, Miller SJ, Gerstbrein J. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol 1998;16:284-9.